At InVivo, we are focused on redefining the treatment of spinal cord injury.

Dr. Toselli serves as InVivo’s President, Chief Executive Officer and Chief Medical Officer, as well as a Director. A board-certified neurological surgeon, Dr. Toselli is passionate about redefining treatment for spinal cord injury and improving on a standard of care that has remained unchanged throughout his 30-year career in spine both in academic practice and industry. Prior to joining InVivo, he served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory and medical affairs teams. Previously, Dr. Toselli served five years at Sanofi in various leadership roles, including Vice President of Global Medical Affairs – Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before Sanofi, he served as Chief Medical/Technology Officer for Covidien Surgical, and earlier held various roles at DePuy Spine including Director of Medical Affairs, Worldwide Vice President of Research and Development and Worldwide Vice President of Clinical Evidence and External Relations. He subsequently held the position of Vice President of Evidence-Based Medicine at Johnson & Johnson for the device sector. Additionally, Dr. Toselli has a depth of experience in academia. His previous academic positions include Assistant Professor at Brown University, Associate Professor, Director of Spine Center, Associate Chief of Staff at the University of North Carolina (UNC) and Associate Professor at the University of Vermont. Dr. Toselli holds a B.A. from Providence College, his M.D. from Brown University and an MBA from the UNC’s Kenan-Flagler Business School.

Mr. Christopher brings more than 25 years of financial experience at a variety of publicly-traded life sciences companies to his role as InVivo’s Chief Financial Officer. Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer. Prior to iCAD Inc., Mr. Christopher was Chief Financial Officer and Chief Operating Officer of Caliber Imaging & Diagnostics, Inc., a medical technology company focused on cancer detection imaging solutions, with primary applications in dermatology. Before Caliber, Mr. Christopher held various positions of increasing responsibility at DUSA Pharmaceuticals, Inc., a Nasdaq-listed dermatology company focused on the treatment of precancerous skin lesions, where he ultimately served as Chief Financial Officer through its acquisition and integration into Sun Pharmaceuticals Industries Ltd. Mr. Christopher holds an M.S. in accounting from Suffolk University and a B.S. in finance from Bentley University.

Ms. Hamel serves as InVivo’s Chief Legal Officer and General Counsel. She leads legal, intellectual property and business development functions, in addition to managing investor relations activities, after holding roles of increasing responsibility since joining the company in 2014. Prior to InVivo, Ms. Hamel worked at Schwegman Lundberg & Woessner, P.A., and at Ecolab, Inc., where she worked on a variety of legal and intellectual property matters, including patent prosecution, intellectual property litigation and patent and trademark licensing activities. Prior to Ecolab, Ms. Hamel worked as a biomaterials research associate at the University of Wisconsin. Ms. Hamel holds a B.S. in chemistry and a B.S. in biochemistry from the University of Wisconsin, a J.D. from William Mitchell College of Law and a Master of Liberal Arts Degree in General Management from Harvard University.

Ms. Merrifield serves as InVivo’s Chair of the Board. She also holds positions both as Chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. She currently serves as a board director for a number of public companies which include Flexion Therapeutics, Lyra Therapeutics, and MassMutual Premier, MML, Select, and MMLII Funds, a portfolio of mutual funds. She also previously served on the board of Juniper Pharmaceuticals until it was acquired by Catalent, and also previously served on the board of Veritas Genetics. Most recently, Ms. Merrifield was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples. Before joining PathoGenetix, Ms. Merrifield served in a number of leadership roles at Genzyme Corporation. In her most recent position, she was selected by the CEO to serve as Senior Vice President, Business Excellence, before the Sanofi acquisition. Prior to that, she served as President of Genzyme Biosurgery, where she led a turnaround from an over $75M loss to a profit of more than $200M. She served as President of Genzyme Genetics before her position at Genzyme Biosurgery, where she shaped the company’s genetic diagnostics business through product and service differentiation and strategic acquisitions. Ms. Merrifield came to Genzyme from Bain and Company, where she was a partner, and Aetna Life & Casualty, where her role was as an investment officer. Ms. Merrifield earned a B.A. in zoology and an M.A. in education from the University of Maine, and an MBA from the Amos Tuck School of Business at Dartmouth College.

Ms. Morrison currently serves as director of InVivo’s Board of Directors and a member of the Audit Committee, as well as a member of the Nominating and Corporate Governance Committee. Ms. Morrison is Chief Financial Officer of Physicians Endoscopy, an ambulatory surgical center management company. Prior to Physicians Endoscopy, Ms. Morrison served as the Senior Vice President of Finance for Aramark. Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and Financial Planning at Merck & Co., Inc., where she was responsible for the company-wide planning, forecasting and budgeting processes, data and process standardization, and developing more automated reporting capabilities. Prior to that, she held the position of Senior Vice President of New Business in the Women’s Health Care division at Wyeth. In that role, she was responsible for the global planning and reporting of the $20 billion pharmaceutical division. Ms. Morrison started her career as an analyst in the Mergers and Acquisitions Department at Alex. Brown & Sons, an investment bank (now Deutsche Bank). During her time at Deutsche Bank, she held increasingly responsible positions, her last being Managing Director, Health Care Group. Ms. Morrison is a member of the Board of Overseers of the Tuck School of Business at Dartmouth College. She is also a Member of the Board of Angel Flight East, a non-profit organization. Ms. Morrison graduated cum laude from the Wharton School at the University of Pennsylvania with a B.S. in economics and the Tuck School of Business at Dartmouth College with an MBA.

Sir Richard Roberts, winner of the 1993 Nobel Prize in Physiology or Medicine, serves on InVivo’s Board of Directors and InVivo’s Scientific Advisory Board. As a Director, Dr. Roberts is also a member of the Compensation Committee, and a member of the Nominating and Corporate Governance Committee. He is the Chief Scientific Officer at New England Biolabs. Sir Richard’s current research interests focus on using bioinformatics and genomics to find new enzyme activities and to drive his experimental program. Most recently, he is involved in a large community-based project called COMBREX aimed at improving the functional annotation of genomes. He has also worked at Cold Spring Harbor Laboratory, reaching the position of Assistant Director for Research under Dr. J.D. Watson. Sir Richard has also been involved in studies of Adenovirus-2, beginning with studies of transcription that led to the discovery of split genes and mRNA splicing, followed by efforts to deduce the DNA sequence of the Adenovirus-2 genome; a complete sequence of 35,937 nucleotides was obtained. The field of DNA methyltransferases is also an area of active research interest. Sir Richard won the 1993 Nobel Prize in Physiology or Medicine for the discovery of split genes, which opened the door to new insights into therapeutic development and human evolution. Sir Richard holds his B.Sc. in chemistry and Ph.D. in organic chemistry from University of Sheffield. His postdoctoral research was carried out in Professor J.L. Strominger’s laboratory at Harvard, where he studied the tRNAs that are involved in the biosynthesis of bacterial cell walls.

Dr. Rosenthal brings more than 25 years of experience to InVivo’s Board of Directors. Currently, Dr. Rosenthal is Director of the Board, Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee for InVivo. Dr. Rosenthal is an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. Currently, he serves as Chairman of the Board of Taconic Biosciences, Inc., where he also held the position of Chief Executive Officer. Additionally, Dr. Rosenthal currently serves as a director of the Bruker Corporation, and a director of Galvanic Applied Sciences, Inc. Previously, Dr. Rosenthal served as a Director of Safeguard Scientifics, Inc., and as Chairman of its Board of Directors. Dr. Rosenthal has also served in a variety of senior management positions with companies involved in the development of therapeutics, medical devices, diagnostics and life sciences tools, most recently as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, and as President and Chief Executive Officer of Magellan Biosciences, Inc. Earlier in his career, Dr. Rosenthal served in senior management positions at PerkinElmer, Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph.D. from Emory University and an M.S. from the State University of New York.

Dr. Toselli serves as InVivo’s President, Chief Executive Officer and Chief Medical Officer, as well as a Director. A board-certified neurological surgeon, Dr. Toselli is passionate about redefining treatment for spinal cord injury and improving on a standard of care that has remained unchanged throughout his 30-year career in spine both in academic practice and industry. Prior to joining InVivo, he served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory, and medical affairs teams. Previously, Dr. Toselli served five years at Sanofi in various leadership roles, including Vice President of Global Medical Affairs – Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before Sanofi, he served as Chief Medical/Technology Officer for Covidien Surgical, and earlier held various roles at DePuy Spine including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. He subsequently held the position of Vice President of Evidence-Based Medicine at Johnson & Johnson for the device sector. Additionally, Dr. Toselli has a depth of experience in academia. His previous academic positions include Assistant Professor at Brown University, Associate Professor, Director of Spine Center, Associate Chief of Staff at the University of North Carolina (UNC), and Associate Professor at the University of Vermont. Dr. Toselli holds a B.A. from Providence College, his M.D. from Brown University, and an MBA from the UNC’s Kenan-Flagler Business School.

Dr. Langer is InVivo’s co-founder and an inventor of the Neuro-Spinal Scaffold^TM. Dr. Langer currently serves as the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), the highest honor that can be awarded to a faculty member. Dr. Langer has written over 1,000 articles and has approximately 1,300 issued and pending patents worldwide. His patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. Dr. Langer has received over 220 major awards, including the United States National Medal of Science; the Charles Stark Draper Prize and the Millennium Technology Prize. He is also the only engineer to receive the Gairdner Foundation International Award. Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and both the National Academy of Engineering and the National Academy of Sciences. He is one of very few people ever elected to all three National Academies. He is the most cited engineer in history (h-index 250 according to Google Scholar).

Additionally, Dr. Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002 and as its Chairman from 1999 to 2002.

Dr. Langer has received honorary doctorates from many prestigious universities including Harvard University, the Mt. Sinai School of Medicine, Yale University and many others. He holds a B.S. from Cornell University and an Sc.D. from the Massachusetts Institute of Technology, both in chemical engineering.

Sir Richard Roberts, winner of the 1993 Nobel Prize in Physiology or Medicine, serves on InVivo’s Board of Directors and InVivo’s Scientific Advisory Board. As a Director, Dr. Roberts is also a member of the Compensation Committee, and a member of the Nominating and Corporate Governance Committee. He is the Chief Scientific Officer at New England Biolabs. Sir Richard’s current research interests focus on using bioinformatics and genomics to find new enzyme activities and to drive his experimental program. Most recently, he is involved in a large community-based project called COMBREX aimed at improving the functional annotation of genomes. He has also worked at Cold Spring Harbor Laboratory, reaching the position of Assistant Director for Research under Dr. J.D. Watson. Sir Richard has also been involved in studies of Adenovirus-2, beginning with studies of transcription that led to the discovery of split genes and mRNA splicing, followed by efforts to deduce the DNA sequence of the Adenovirus-2 genome; a complete sequence of 35,937 nucleotides was obtained. The field of DNA methyltransferases is also an area of active research interest. Sir Richard won the 1993 Nobel Prize in Physiology or Medicine for the discovery of split genes, which opened the door to new insights into therapeutic development and human evolution. Sir Richard holds his B.Sc. in chemistry and Ph.D. in organic chemistry from University of Sheffield. His postdoctoral research was carried out in Professor J.L. Strominger’s laboratory at Harvard, where he studied the tRNAs that are involved in the biosynthesis of bacterial cell walls.

Dr. Guest brings extensive contributions to the field of spinal cord injury, both in terms of medical practice and research, to InVivo. He is currently a Professor of Neurological Surgery at the Miller School of Medicine and the Miami Project to Cure Paralysis in Miami, FL. Previously, Dr. Guest held numerous hospital appointments, such as Attending Neurosurgeon at the Barrow Neurological Institute, West Palm Beach VA Medical Center and the University of Miami Hospital and Chief of Spinal Neurosurgery at Miami Veterans Medical Center. Dr. Guest has authored over 75 peer-reviewed publications, including articles, book chapters and abstracts in the areas of cellular therapy for spinal cord injury, biology of neuroglia and mechanisms of secondary injury. He has been active in research design for human clinical trials, participating as a Principal Investigator for the North American Clinical Trials Network (NACTN) for the Treatment of Spinal Cord Injury. Dr. Guest earned a B.A. in economics and political science, a B.S. in chemistry and biology and a Medical Degree from the University of Alberta. He also earned a Ph.D. from the University of Miami, Department of Neuroscience. Dr. Guest completed his residency in the Division of Neurosurgery at the University of British Columbia and a fellowship in Spinal Surgery at the Barrow Neurological Institute.

Dr. Edgerton serves as a member of the Scientific Advisory Board at InVivo and is the Director of UCLA’s Edgerton Lab researching neural networks in the lumbar spinal cord after complete spinal cord injury. Dr. Edgerton is also a professor in the Department of Physiological Sciences at UCLA researching neural control of movement adaptations after spinal cord injury. While a professor at UCLA, Dr. Edgerton served as chair of his department. He has also served as a visiting professor at the University of Goteborg in Sweden, Tokyo Metropolitan Neuroscience Institute and the Panum Institute of the University of Copenhagen. He received a Citation Award from the American College of Sports Medicine and has served NASA in a number of roles. In addition to serving on the board of the CRF, he is currently on the scientific advising board of the American Paralysis Association. Dr. Edgerton has co-authored two books and is the author of approximately 300 research papers. Dr. Edgerton is on the Scientific Advisory Board of the Christopher Reeve Foundation (CRF), and his is one of eight labs in the world receiving funding from the CRF. He completed his Ph.D. under the direction of Drs. Wayne Van Huss, Rex Carrow and William Heusner at Michigan State University.